Low-temperature isothermal amplification of polynucleotides

Specially designed primers and enzymes facilitate robust isothermal amplification and detection of target polynucleotides at low temperatures, addressing the limitations of existing technologies and enhancing the sensitivity and reliability of at-home nucleic acid testing.

JP2024544697APending Publication Date: 2024-12-03MASSACHUSETTS INST OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534185
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-08
Filing Date
2022-12-07
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing point-of-care nucleic acid testing products for at-home use require improvements in isothermal amplification technology to function effectively at low temperatures, such as 12-25°C, to enable robust and cost-effective detection of target polynucleotides associated with diseases like COVID-19.

Method used

The use of specially designed primers that inhibit primer dimer formation at low temperatures through the inclusion of short hybridization sequences, nickase recognition sequences, and 3' blocking molecules, combined with strand displacement polymerases and single-strand binding proteins, allows for robust isothermal amplification and detection of target polynucleotides.

Benefits of technology

This approach enables efficient amplification and detection of target polynucleotides at low temperatures, achieving attomolar sensitivity and stability, even in the presence of background nucleic acids, with improved detection limits and reduced primer dimer formation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544697000001_ABST
    Figure 2024544697000001_ABST
Patent Text Reader

Abstract

In some aspects, the present disclosure provides methods and compositions for isothermal low-temperature amplification of target polynucleotides and for their detection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 63 / 287,437, filed December 8, 2021, which is incorporated by reference in its entirety.

[0002] Electronic Sequence Listing Reference The contents of the electronic sequence listing (H049870749WO00-SEQ-HJD.xml; size: 7,196 bytes; and creation date: December 2, 2022) are incorporated herein by reference in their entirety. [Background technology]

[0003] background As the SARS-CoV-2 pandemic continues, the need for at-home point-of-care (POC) nucleic acid testing products (NATs) that can be sold directly to consumers has become increasingly apparent. A handful of such products are now commercially available, taking advantage of advances in NAT-related technologies, but significant improvements to the available underlying technologies are needed. Summary of the Invention [Means for solving the problem]

[0004] overview Provided herein, in some aspects, are compositions and methods for isothermal amplification of target polynucleotides that are robust at low temperatures (e.g., 12-25°C). Low-temperature isothermal amplification of target polynucleotides is a key step for implementing low-cost home tests to detect target polynucleotides associated with diseases such as COVID-19 caused by SARS-CoV-2 infection. Low-temperature target polynucleotide amplification is achieved, at least in part, using primers specifically designed to inhibit primer-dimer formation at low temperatures.

[0005] The primers provided herein, in some embodiments, comprise a short (e.g., 10-30 nucleotides) hybridization sequence that is complementary to a primer binding sequence on a target polynucleotide. The hybridization sequence, in some embodiments, further comprises a nickase recognition sequence (e.g., a portion or the complete sequence of a nickase recognition sequence). In some embodiments, the primer also comprises a stabilizing sequence 5' to the nickase recognition sequence. In some embodiments, the primer further comprises a 3' blocking molecule that terminates polymerization, thereby blocking amplification of the primer dimer. In some embodiments, the 3' blocking molecule is subsequently removed from the primer using a nickase and a strand-displacing polymerase to allow 3' extension of the primer, as described below.

[0006] The target polynucleotide to be amplified and detected, in some embodiments, comprises (e.g., is modified to comprise) a primer binding sequence located near (e.g., within 50 nucleotides) the 5' end of the target polynucleotide and / or near (e.g., within 50 nucleotides) the 3' end of the target polynucleotide. In some embodiments, the target polynucleotide to be amplified and detected comprises (e.g., is modified to comprise) a primer binding sequence located at the 3' end of the target polynucleotide. In some embodiments, the target polynucleotide primer binding sequence comprises a nickase recognition sequence, which can be a partial sequence of the nickase recognition sequence or the complete sequence of the nickase recognition sequence.

[0007] An example of the method provided herein is depicted in Figures 1A-1J. Without being bound by theory, a primer first binds to a primer binding sequence of a target polynucleotide. For example, a primer may bind to a primer binding sequence on a target polynucleotide that includes a nickase recognition sequence (Figure 1A). In some embodiments, a primer binds to a primer binding sequence within 50 nucleotides of the 5' end of the target polynucleotide, and a strand displacing polymerase adds the reverse complement of the primer to the target polynucleotide by extending in the 3' to 5' direction (Figure 1B). The nickase, in some embodiments, then binds to the newly formed double-stranded target polynucleotide and nicks the primer, which allows the strand displacing polymerase to remove the 3' blocking molecule and extend the primer (Figures 1C-1D). Extension of the remaining portion of the target polynucleotide forms a double-stranded target polynucleotide that includes a primer stabilizing sequence and a nickase recognition sequence (Figure 1E). Amplification of the target polynucleotide can continue by repeated cycles of nicking and extension. A single-stranded DNA binding protein is added in some embodiments to stabilize the displaced strand during extension (FIG. 1F). In some embodiments, the repeated nicking and extension results in the repeated creation of the reverse complement of the target polynucleotide (FIG. 1G). In some embodiments, the primer also binds to the reverse complement of the target polynucleotide (FIG. 1H). In some embodiments, a second primer binds to the reverse complement of the target polynucleotide. This results in the nicking and extension of a copy of the reverse complement of the target polynucleotide, creating a copy of the target polynucleotide (FIGS. 1I-1J). This results in exponential amplification of the target polynucleotide. In some embodiments, copies of the target polynucleotide (or the reverse complement of the target polynucleotide) created by the amplification are detected, for example, using the detection methods described herein. Unlike conventional techniques, this amplification and detection scheme is robust under isothermal conditions at low temperatures.

[0008] Some embodiments of the present disclosure provide compositions comprising: (a) a target polynucleotide comprising a primer binding sequence, wherein the primer binding sequence comprises a nickase recognition sequence; (b) a primer comprising a hybridization sequence complementary to the primer binding sequence, wherein (i) the primer further comprises a 3' blocking molecule, and / or (ii) the hybridization sequence consists of 8 to 12 contiguous nucleotides complementary to the primer binding sequence.

[0009] In some embodiments, the target polynucleotide is single-stranded.

[0010] In some embodiments, the nickase recognition sequence is a partial or complete nickase recognition sequence.

[0011] In some embodiments, the primer binding sequence is in the 5' terminal region of the target polynucleotide.

[0012] In some embodiments, the target polynucleotide comprises an additional sequence that is the reverse complement of the primer binding sequence.

[0013] In some embodiments, the additional sequence is in the 3' terminal region of the target polynucleotide.

[0014] In some embodiments, the 3' blocking molecule is selected from 3' hexanediol, 3' ddC, 3' Inverted dT, 3' carbon chain spacer, 3' amino, 3' phosphorylation.

[0015] In some embodiments, the primer further comprises a stabilizing sequence 5' to the nickase recognition sequence, optionally the stabilizing sequence consisting of 6 to 30 nucleotides or 18 nucleotides.

[0016] In some embodiments, the target polynucleotide is present in the composition at a concentration of less than 100 attomoral.

[0017] In some embodiments, the composition further comprises a cognate nickase, a single-stranded binding protein, a strand-displacing polymerase, or any combination thereof.

[0018] In some embodiments, the cognate nickase is selected from Nb.BbvCI, Nt.BspQI, Nt.CviPII, Nt.BstNBI, Nb.BsrDI, Nb.BtsI, Nt.AlwI, Nt.BbvCI, Nb.BsmI, Nb.BssSI, and Nt.BsmAI.

[0019] In some embodiments, the single-stranded binding protein is selected from T4 gene 32 protein (T4gp32), Tth RecA, and ET SSB.

[0020] In some embodiments, the strand displacement polymerase is selected from Bsu DNA polymerase I (Bsu), phi29, Bst DNA polymerase, Klenow Large Fragment, Klenow Exo-, Bsu Large Fragment, Isopol, and Isopol SD+.

[0021] In some embodiments, the composition further comprises (i) a Cas13a or Cas13b protein, (ii) a detector polynucleotide comprising a sequence flanked by a detectable molecule and a quencher molecule, (iii) a crRNA, and (iv) an RNA polymerase, wherein the target polynucleotide further comprises a cognate RNA polymerase binding sequence, and the crRNA comprises a sequence that binds to RNA transcribed from the target polynucleotide.

[0022] Another aspect of the present disclosure provides a method that includes incubating a composition provided herein in a buffer to generate multiple copies of a target polynucleotide.

[0023] In some embodiments, the incubating is at about 4°C to about 50°C, about 4°C to about 45°C, about 4°C to about 40°C, about 4°C to about 35°C, about 4°C to about 30°C, or about 16°C to about 25°C.

[0024] In some embodiments, the incubation is under isothermal conditions.

[0025] In some embodiments, the method further comprises detecting multiple copies of the target polynucleotide, optionally, the detecting using Specific High Sensitivity Enzyme Reporter Unlocking (SHERLOCK).

[0026] Yet another aspect of the present disclosure provides a method comprising incubating a composition provided herein in a buffer to generate multiple copies of a target polynucleotide, and then incubating the multiple copies of the target polynucleotide with a Cas12a protein, a crRNA, and a detector polynucleotide comprising a detector sequence flanked by a detectable molecule and a quencher molecule, wherein the crRNA comprises a sequence that binds to the target polynucleotide or a reverse complement sequence of the target polynucleotide.

[0027] In some embodiments, the method further comprises detecting multiple copies of the target polynucleotide, optionally, the detecting using Specific High Sensitivity Enzyme Reporter Unlocking (SHERLOCK). [Brief description of the drawings]

[0028] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1A] 1A-1J show schematics of amplification of a target oligonucleotide: Figure 1A shows a schematic of a primer including a 3' blocking molecule. [Figure 1B] FIG. 1B shows the extension of a target oligonucleotide using a primer as a template and a BSU. [Figure 1C] FIG. 1C shows a primer nicked by nickase. [Figure 1D]FIG. 1D shows Bsu extending a primer downwards using the target polynucleotide as a template, displacing the nicking portion of the primer that contains the 3′ blocking group. [Figure 1E] FIG. 1E shows the nicking of the double-stranded target polynucleotide product from FIG. 1D. [Figure 1F] FIG. 1F shows amplification of a double-stranded target polynucleotide product using BSU and stabilization of the displaced strand by a single-stranded binding protein (SSBP). [Figure 1G] FIG. 1G shows the results of repeated amplification from a double-stranded target polynucleotide product. [Figure 1H] FIG. 1H shows a primer that includes a 3' blocking molecule that binds to a single-stranded reverse complement sequence of a target polynucleotide. [Figure 1I] FIG. 1I shows the nicking of double-stranded DNA created by extension of the reverse complement of the target polynucleotide created in FIG. 1H. [Figure 1J] FIG. 1J shows the repetitive nicking and extension of the reverse complement of a target polynucleotide. [Diagram 2] Figure 2 shows that the CRISPR-Cas9-induced nicking endonuclease-mediated strand displacement amplification (CRISDA) platform is not robust at low temperatures. CRISDA is a state-of-the-art ambient temperature strand displacement amplification (SDA) using existing primer designs. The same amplification reactions as described in the CRISDA literature (Zhou, Wenhua, et al. Nature Communications, vol. 9, no. 1, 2018) were performed with varying primer length, primer concentration, and single-stranded binding protein (T4gp32) concentration as indicated. The fold change in signal from the second-stage Cas12a detection reaction is shown with different concentrations of input ssDNA trigger (0 attomoral (aM), 20aM, 2fM, 200fM). [Diagram 3]Figure 3 shows that decreasing primer length reduces primer dimer formation. Time course of strand displacement amplification (SDA) primer dimer formation at room temperature. Agarose gels (4%) of SDA reactions stopped (by heat killing at 80°C) at the indicated time points are shown for three pairs of primers of different lengths (20 nucleotides (nt), 17 nt, and 14 nt). The red arrows and red text indicate the time of formation of nickase extension products smaller than the initial starting primer. [Figure 4A] Figures 4A-B show the design of new primers with a short hybridization sequence of 9 nt. Left in Figure 4A: The primers are designed to dimerize such that the nickase recognition sequence (BbvCI) does not completely overlap. Right: The primers dimerize such that the nickase recognition sequence is excluded from the hybridization sequence, forming a dimeric species that self-amplifies exponentially with the nickase recognition sequence. [Figure 4B] FIG. 4B: Previous designs for strand displacement amplification employ two primers with a hybridization sequence (black) and a nickase recognition sequence (green) and a stabilizing sequence (pink). These primers are long enough to allow the formation of a dimeric species that amplifies exponentially. However, the improved short single primer design described herein forms only an inactive, non-amplified dimeric species. This is made possible by attaching a primer binding sequence (blue) to the 3' and 5' ends of the target polynucleotide. In some embodiments, the primer binding sequences at the 3' and 5' ends of the target polynucleotide are identical sequences. In some embodiments, the primer binding sequences at the 3' and 5' ends of the target polynucleotide are different sequences. At this time, a nickase recognition sequence (green) can also be added. The primer binding sequence and the nickase recognition sequence can be added to the target polynucleotide by various means, including the use of bump primers, ligase splints, etc. The removal of the target specific region and the integration of the two primers allows the use of short primers in ways that would not normally be possible. [Diagram 5] Figure 5 suggests that the short primer design does not result in exponential primer dimer amplification. Time course of primer dimer formation at room temperature using the new primer design. Agarose gels (4%) of reactions stopped (by heat killing at 80°C) at the indicated time points are shown for a single shortened 9 nt forward primer. Red text indicates when primer dimers form, which is not specifically nickase generated (such products are smaller than the starting primer, rather than dramatically larger). [Figure 6A] Figures 6A-6B show ambient temperature detection of single-stranded DNA (ssDNA) target polynucleotides using Cas12a and short primers. Figure 6A shows a schematic of a two-pot reaction for amplification and detection of target polynucleotides using Cas12a. ssDNA target polynucleotides were amplified for 2 h at room temperature using short primers. After amplification, crRNA:Cas12a complexes targeting PAM-containing sequences on the amplicon were added to the reaction and cleaved the fluorophore quencher reporter (e.g., detector polynucleotide) for 30 min. [Figure 6B] Figure 6B shows quantification of detection for various amounts of starting ssDNA target polynucleotide. Individual values ​​and the average of six replicates are shown (n=6). [Figure 7A] Figures 7A-7C show ambient temperature detection of ssDNA target polynucleotides using Cas13a and amplification with short primers. Figure 7A shows one-pot amplification and detection of ssDNA target polynucleotides using Cas13a. ssDNA target polynucleotides were amplified at room temperature using primers and T7 RNA polymerase (RNAP) was added to the system. During amplification, the crRNA:Cas13a complex present in the reaction detected the transcribed RNA copy of the target polynucleotide and cleaved the fluorophore quencher reporter (i.e., detector polynucleotide) in response. The actual reaction start time was 45 min before t=0. [Figure 7B]FIG. 7B shows detection of target polynucleotide copies over time for various amounts of starting target polynucleotide. [Figure 7C] Figure 7C shows the temperature sensitivity of the assay from 20° C. to 12° C. Individual time courses of four replicates are shown (n=4). [Figure 8] Figure 8 shows ambient temperature detection of single-stranded target polynucleotides using Cas13a and primers with 3' blocking molecules. Single-stranded target polynucleotides were amplified at room temperature using short primers with either unblocked 3'OH or 3' hexanediol blocking molecules in the presence or absence of background single-stranded DNA (ssDNA) oligos (25 nM). During amplification, the crRNA:Cas13a complex present in the reaction detected the transcribed RNA copy of the target polynucleotide and cleaved the detector polynucleotide in response. The actual reaction start time was 80 min before placing the reaction on the plate reader. Individual time courses of single replicates are shown (n=1). [Figure 9] Figure 9 shows that femtomolar (fM) amounts of target polynucleotides can be detected using different strand-displacing polymerases. Amplified copies of target polynucleotides were detected using an enzymatic fluorophore quencher assay. Reactions were performed at ambient temperature using short 3' blocked primers (10 nt hybridization sequence, 18 nt stabilization sequence) and Cas13 fluorescence was detected in a one-pot reaction following a T7 transcription step. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] Detailed Description In some aspects, the present disclosure relates to compositions and methods for isothermal low-temperature amplification of target polynucleotides, hi some embodiments, amplification is followed by detection of copies of the target polynucleotide.

[0030] composition Provided herein in some aspects are compositions that can be used to amplify a target polynucleotide, for example, at ambient temperature in isothermal conditions. The compositions, in some embodiments, include a target polynucleotide and a primer designed to specifically bind to the target polynucleotide (e.g., flanking a sequence of interest). The compositions, in some embodiments, also include a nickase, a single-stranded binding protein, and / or a strand-displacing polymerase, each of which is described below.

[0031] In some embodiments, a molecule for detection of the amplified target polynucleotide is also included in the composition or added to the composition. For example, the composition may further include a detector polynucleotide flanked by a detectable molecule and a quencher molecule. In some embodiments, the detector polynucleotide includes an endonuclease recognition sequence. In some embodiments, the detector polynucleotide is included in the composition together with Cas12 endonuclease or together with Cas13 endonuclease and RNA polymerase. In some embodiments, the detector polynucleotide is cleaved by the secondary activity of Cas12 endonuclease or Cas13 endonuclease, as described in Kellner et al. Nature protocols 14.10 (2019): 2986-3012, which is incorporated herein by reference in its entirety.

[0032] Target Polynucleotide The disclosed method is used to amplify a target polynucleotide. The target polynucleotide can be DNA or RNA, or a hybrid of DNA and RNA. In some embodiments, the target polynucleotide is RNA, such as mRNA, non-coding RNA, or ribosomal RNA. In some embodiments, the target polynucleotide is single-stranded. In other embodiments, the target polynucleotide is double-stranded. In still other embodiments, the target polynucleotide is partially double-stranded (i.e., includes single-stranded and double-stranded regions).

[0033] In some embodiments, the target polynucleotide is derived from a pathogen. Pathogens are generally known to be bacteria, viruses, or other microorganisms that can cause disease. In some embodiments, the target polynucleotide is a viral polynucleotide. For example, the target polynucleotide may be derived from a virus, such as a betacoronavirus, one non-limiting example of which is SARS-CoV-2. In other embodiments, the target polynucleotide is a bacterial polynucleotide. In yet other embodiments, the target polynucleotide is a fungal polynucleotide. In yet other embodiments, the target polynucleotide is a protozoan or parasitic polynucleotide. In some embodiments, the target polynucleotide is specific to a pathogen, such that detection of the target polynucleotide indicates the presence of the particular pathogen.

[0034] In some embodiments, the target polynucleotide is present in a sample derived from (e.g., obtained from) a subject. A "subject" includes, but is not limited to, humans and other non-human animals, including, for example: companion animals such as dogs, cats, domestic pigs, ferrets, and hamsters; primates such as cynomolgus monkeys and rhesus monkeys; and agricultural animals such as cows, pigs, horses, sheep, goats, and poultry (e.g., chickens, ducks, geese, and / or turkeys). In some embodiments, the subject is a human subject.

[0035] The sample, in some embodiments, is selected from blood, urine, saliva, and mucus. In some embodiments, the sample is a blood sample. In other embodiments, the sample is a urine sample. In yet other embodiments, the sample is a saliva sample. In yet other embodiments, the sample is a mucus sample.

[0036] In some embodiments, the compositions and methods disclosed herein provide for robust amplification of target polynucleotides. Robust amplification of target polynucleotides refers to compositions and methods that consistently amplify target polynucleotides to detectable levels. Consistent amplification is evidenced by reproducible success in amplifying and detecting target polynucleotides, for example, as illustrated in Example 2. Those skilled in the art will appreciate that robustness depends on the starting concentration of target polynucleotides in the composition or method. For example, the compositions and methods described herein are generally expected to robustly amplify and detect attomolar amounts of target polynucleotides, for example, at least 2 aM, at least 3 aM, at least 4 aM, at least 5 aM, at least 10 aM, at least 20 aM, at least 50 aM, or at least 100 aM of target polynucleotides.

[0037] In some embodiments, the target polynucleotide is present in the sample at a concentration of at least 2 attomoral (aM). For example, the target polynucleotide may be present in the sample at a concentration of at least 2 aM, at least 3 aM, at least 4 aM, at least 5 aM, at least 10 aM, at least 20 aM, at least 50 aM, or at least 100 aM. In some embodiments, the target polynucleotide is present in the sample at a concentration of 2-5 aM, 2-10 aM, 2-20 aM, 2-40 aM, 2-100 aM, 5-10 aM, 5-20 aM, 5-40 aM, 5-100 aM, 10-20 aM, 10-50 aM, 20-50 aM, 10-100 aM, 50-100 aM, 1-1000 aM, 5-1000 aM, or 50-1000 aM. In some embodiments, a sample contains other molecules in addition to the target polynucleotides, for example other non-target polynucleotides.

[0038] Primer binding sequence In some embodiments, the target polynucleotide comprises one or more primer binding sequences. For example, the target polynucleotide may comprise a first primer binding sequence and a reverse complement of a second primer binding sequence, and the first primer binding sequence and the reverse complement of the second primer binding sequence are adjacent to the sequence of interest. The sequence of interest refers to a sequence in the target polynucleotide that is specifically amplified. This sequence may include a sequence that is bound by the CRISPR Cas complex during detection. The first primer binding sequence and the reverse complement of the second primer binding sequence are considered to be "adjacent" to the sequence of interest when one primer binding sequence (or its reverse complement) is upstream (5') of the sequence of interest and the other primer binding sequence (or its reverse complement) is downstream (3') of the sequence of interest. This configuration allows polymerase-based amplification of the intervening sequence of interest. It should be understood that embodiments describing a "primer binding sequence" encompass a "first primer binding sequence," a "reverse complement of a second primer binding sequence," and any additional primer binding sequences that may be contemplated.

[0039] In some embodiments, the primer binding sequence comprises 8-12 contiguous nucleotides. Contiguous nucleotides are nucleotides that are contiguous in the primary sequence of the target polynucleotide, with no additional intervening nucleotides or other molecules between the contiguous nucleotides. In some embodiments, the primer binding sequence comprises 8-9, 8-10, 8-11, 8-12, 9-10, 9-11, 9-12, 10-11, 10-12, or 11-12 contiguous nucleotides. In some embodiments, the primer binding sequence comprises 9-11 contiguous nucleotides. In some embodiments, the primer binding sequence comprises 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more contiguous nucleotides. In some embodiments, the primer binding sequence comprises 8 to 13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to 20, 8 to 21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27, 8 to 28, 8 to 29, or 8 to 30 consecutive nucleotides. In some embodiments, the primer binding sequence comprises 8 consecutive nucleotides. In some embodiments, the primer binding sequence comprises 9 consecutive nucleotides. In some embodiments, the primer binding sequence comprises 10 consecutive nucleotides. In some embodiments, the primer binding sequence comprises 11 consecutive nucleotides. In some embodiments, the primer binding sequence comprises 12 consecutive nucleotides.

[0040] In some embodiments, the primer binding sequence is attached to the 5'-terminal nucleotide of the target polynucleotide. In some embodiments, the primer binding sequence is located within the 5'-terminal region of the target polynucleotide. In some embodiments, the 5'-terminal region of the target polynucleotide refers to the 7, 8, 9, 10, 11, 12, or 13 nucleotides closest to the 5'-end. In some embodiments, the 5'-terminal region of the target polynucleotide refers to the 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides closest to the 5'-end of the target polynucleotide. In some embodiments, the primer binding sequence is located within 10 nucleotides of the 5'-terminal region of the target polynucleotide. In some embodiments, the primer binding sequence is located within 25 nucleotides of the 5'-terminal region of the target polynucleotide. In some embodiments, the primer binding sequence is located within 50 nucleotides of the 5'-terminal region of the target polynucleotide.

[0041] In some embodiments, the primer binding sequence is attached to the 3' terminal nucleotide of the target polynucleotide. In some embodiments, the primer binding sequence is located within the 3' end of the target polynucleotide. In some embodiments, the 3' end of the target polynucleotide refers to the 7, 8, 9, 10, 11, 12, or 13 nucleotides closest to the 3' end. In some embodiments, the 3' end of the target polynucleotide refers to the 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides closest to the 3' end. In some embodiments, the 3' end of the target polynucleotide refers to the 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides closest to the 3' end of the target polynucleotide. In some embodiments, the primer binding sequence is located within 10 nucleotides of the 3' end of the target polynucleotide. In some embodiments, the primer binding sequence is located within 25 nucleotides of the 3' end of the target polynucleotide. In some embodiments, the primer binding sequence is located within 50 nucleotides of the 3' end of the target polynucleotide.

[0042] In some embodiments, the primer binding sequence comprises a nickase recognition sequence. In some embodiments, the primer binding sequence comprises a complete or partial sequence of a nickase recognition sequence (as described below). In some embodiments, the primer binding sequence comprises the reverse complement of a nickase recognition sequence. In some embodiments, the nickase recognition sequence is selected from 5'-CCTCAGC-3' (Nb.BbvCI), 5'-GCTCTTC-3' (Nt.BspQI), 5'-CCT-3', 5'-CCG-3', or 5'-CCA-3' (Nt.CviPII), 5'-GAGTCNNNNN-3' (Nt.BstNBI), 5'-GCAATGNN-3' (Nb.BsrDI), 5'-GCAGTGNN-3' (Nb.BtsI), 5'-GGATCNNNNN-3' (Nt.AlwI), 5'-GAATGCN-3' (Nb.BsmI), 5'-CACGAG-3' (Nb.BssSI), and 5'-GTCTCNN-3' (Nt.BsmAI). In some embodiments, the primer binding sequence comprises '5-CCTCAGC-3' which can be nickled by Nb.BbvCI. In some embodiments, the primer binding sequence comprises a partial Nb.BbvCI nickase recognition sequence (bold). [ka] (SEQ ID NO:1). In some embodiments, the primer binding sequence is within 5, 10, 25, or 50 base pairs of the sequence of interest or at the 5' end of the target polynucleotide. In some embodiments, the primer binding sequence is within 5, 10, 25, or 50 base pairs of the sequence of interest or at the 3' end of the target polynucleotide.

[0043] In some embodiments, the target polynucleotide comprises a primer binding sequence and an additional sequence. In some embodiments, the additional sequence is a reverse complement of the primer binding sequence. In some embodiments, the additional sequence is the same sequence as the primer binding sequence when reverse transcribed. Thus, in some embodiments, the additional sequence is a primer binding sequence on the reverse complement of the target polynucleotide. In some embodiments, the additional sequence comprises a reverse complement of the complete or partial sequence of the nickase recognition sequence described above. In some embodiments, the additional sequence comprises a sequence of 5'-TGAGGAGGAG-3' (SEQ ID NO:2). In some embodiments, the additional sequence is located within the 3' terminal region of the target polynucleotide. In some embodiments, the additional sequence is located within the 5' terminal region of the target polynucleotide. In some embodiments, the additional sequence comprises a sequence that is not a reverse complement of the primer binding sequence. In some embodiments, the primer binding sequence and the reverse complement of the additional sequence are orthogonal sequences. The term "orthogonal" refers to two or more nucleic acid molecules that are insufficiently complementary to hybridize to one another to a significant extent, as compared to a nucleic acid molecule that comprises a complementary sequence.

[0044] In some embodiments, the target polynucleotide comprises the sequence 5'-TGAGGAGGAGNNN...NNNCTCCTCCTCA-3' (SEQ ID NOs: 6-7), where NNN...NNN is the sequence of interest. The sequence of interest is flanked by primer binding sequences that, in some embodiments, are reverse complementary to each other: 5'-TGAGGAGGAG-3' (SEQ ID NO: 2) and 5'-CTCCTCCTCA-3' (SEQ ID NO: 1). One of skill in the art will appreciate that the length of the sequence of interest can vary. In some embodiments, the sequence of interest is 15-50, 15-100, 15-150, 15-200, 15-300, 20-50, 20-100, 20-150, 20-200, 20-300, 50-100, 50-150, 50-200, 50-300, 100-150, 100-200, or 100-300 nucleotides in length. In some embodiments, the sequence of interest is at least 15 nucleotides in length. In some embodiments, the sequence of interest is at least 18 nucleotides in length. In some embodiments, the sequence of interest is at least 20 nucleotides in length. In some embodiments, the sequence of interest is of sufficient length to be detectable using Cas12 or Cas13, or variants thereof.

[0045] Binding of the primer binding sequence to the target polynucleotide In some embodiments, the primer binding sequence is attached to the target polynucleotide. In some embodiments, the primer binding sequence is attached to the target polynucleotide using known methods, such as restriction enzyme digestion / ligation or blunt end ligation. In some embodiments, the primer binding sequence is attached to the target polynucleotide using the isothermal ligation method described in Gibson et al. "Nature methods 6.5 (2009): 343-345, which is incorporated by reference in its entirety. In some embodiments, the primer binding sequence is attached to the target polynucleotide using the isothermal ligation method described in Kershaw et al. Recombinant and In Vitro RNA Synthesis. Humana Press, Totowa, NJ, 2013. The primer-binding sequence is attached to the target polynucleotide using splint ligation as described in, for example, U.S. Pat. No. 2,257-269. In some embodiments, the first primer-binding sequence is attached to the 5' end of the target polynucleotide, and an additional sequence comprising the reverse complement of the second primer-binding sequence is attached to the 3' end of the target polynucleotide. In some embodiments, the first primer-binding sequence is attached to the 3' end of the target polynucleotide, and an additional sequence comprising the reverse complement of the second primer-binding sequence is attached to the 5' end of the target polynucleotide. In some embodiments, the attachment of the primer-binding sequence to the target polynucleotide is performed under isothermal and low-temperature conditions. Those skilled in the art will understand that the additional sequence can be attached to the target polynucleotide using the same or substantially similar method as the method used to attach the primer-binding sequence to the target polynucleotide.

[0046] RNA polymerase binding sequence In some embodiments, detection of the amplified sequence of interest includes the use of an RNA polymerase, such as T7 RNA polymerase. In such embodiments, the target polynucleotide further includes an RNA polymerase binding sequence. In some embodiments, the target polynucleotide is modified to include an RNA polymerase binding sequence. In some embodiments, the RNA polymerase binding sequence is added to the target polynucleotide using a primer during amplification that includes a stabilizing sequence that includes an RNA polymerase binding sequence. In some embodiments, the RNA polymerase binding sequence is added to the target polynucleotide as part of a primer binding sequence or an additional sequence.

[0047] In some embodiments, the RNA polymerase binding sequence is homologous to the RNA polymerase contained in the composition. In some embodiments, the RNA polymerase binding sequence is a bacterial RNA polymerase binding sequence. In some embodiments, the RNA polymerase binding sequence is a eukaryotic RNA polymerase binding sequence. In some embodiments, the RNA polymerase binding sequence is a bacteriophage RNA polymerase binding sequence. In some embodiments, the RNA polymerase binding sequence is an RNA polymerase I, RNA polymerase II, RNA polymerase III, RNA polymerase IV, RNA polymerase V, Nr virion RNA polymerase, or T7 RNA polymerase binding sequence. In some embodiments, the RNA polymerase binding sequence is a T7 RNA polymerase binding sequence.

[0048] Primer The method provided herein uses one or more primers to amplify target polynucleotides. For example, the composition may include a primer. It should be understood that the embodiment that describes "primer" includes "first primer", "second primer", and any additional primer that may be considered.

[0049] Hybridization sequence The primer comprises a hybridization sequence that is complementary to the primer binding sequence in the target polynucleotide. Thus, in some embodiments, the single-stranded target polynucleotide comprises (or is modified to comprise) a primer binding sequence to which the hybridization sequence binds. Following the binding of the primer to the single-stranded target polynucleotide and subsequent polymerase-based extension, a reverse complement of the target polynucleotide is generated. In some embodiments, the reverse complement of the target polynucleotide comprises the same primer binding sequence as the target polynucleotide. Following this, the same primer may bind to the single-stranded target polynucleotide and the reverse complement of the single-stranded target polynucleotide. The extension of the single-stranded target polynucleotide and the reverse complement results in exponential amplification of the target polynucleotide.

[0050] In some embodiments, the composition comprises a primer. In some embodiments, the primer comprises a hybridization sequence. Hybridization sequence refers to a sequence that is complementary to a primer binding sequence of a target polynucleotide. In some embodiments, the hybridization sequence is at least 85% (e.g., at least 85%, at least 90%, at least 95%, or at least 99%) complementary to a primer binding sequence of a target polynucleotide. In some embodiments, the hybridization sequence is 100% complementary to a primer binding sequence of a target polynucleotide. In some embodiments, the primer comprises a hybridization sequence that is complementary to a reverse complement of an additional sequence (e.g., a primer binding sequence) of a target polynucleotide. In some embodiments, the hybridization sequence comprises a sequence that is a nickase recognition sequence. In some embodiments, the hybridization sequence comprises a sequence selected from 5'-CCTCAGC-3' (Nb.BbvCI); 5'-GCTCTTC-3' (Nt.BspQI); 5'-CCT-3', 5'-CCG-3', or 5'-CCA-3' (Nt.CviPII); 5'-GAGTCNNNNN-3' (Nt.BstNBI); 5'-GCAATGNN-3' (Nb.BsrDI); 5'-GCAGTGNN-3' (Nb.BtsI); 5'-GGATCNNNNN-3' (Nt.AlwI); 5'-GAATGCN-3' (Nb.BsmI); 5'-CACGAG-3' (Nb.BssSI); and 5'-GTCTCNN-3' (Nt.BsmAI), or a sequence which is the reverse complement of one of these nickase recognition sequences. In some embodiments, the hybridization sequence comprises a sequence that is the reverse complement of the Nb.BbvCI (5'-CCTCAGC-3') sequence. In some embodiments, the hybridization sequence comprises a complete or partial sequence of a nickase recognition sequence (or its reverse complement). In some embodiments, the hybridization sequence comprises a complete or partial sequence of a nickase recognition sequence (or its reverse complement) and 2, 3, 4, 5, 6, 7, or 8 additional nucleotides.In some embodiments, the hybridization sequence comprises a complete or partial sequence (or a reverse complement) of the nickase recognition sequence and 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 4-5, 4-6, 4-7, 4-8, 4-9, 5-6, 5-7, 5-8, 5-9, 6-7, 6-8, 6-9, 7-8, 7-9, or 8-9 additional nucleotides. In some embodiments, the hybridization sequence comprises a complete or partial sequence (or a reverse complement) of the nickase recognition sequence and 4-6 additional nucleotides. In some embodiments, the hybridization sequence comprises 8-9, 8-10, 8-11, 8-12, 9-10, 9-11, 9-12, 10-11, 10-12, or 11-12 nucleotides. In some embodiments, the hybridization sequence comprises 9-11 nucleotides. In some embodiments, the hybridization sequence comprises 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the hybridization sequence comprises 8-13, 8-14, 8-15, 8-16, 8-17, 8-18, 8-19, 8-20, 8-21, 8-22, 8-23, 8-24, 8-25, 8-26, 8-27, 8-28, 8-29, or 8-30 nucleotides. In some embodiments, the hybridization sequence comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 nucleotides. In some embodiments, the hybridization sequence comprises 9, 10, or 11 nucleotides. In some embodiments, the hybridization sequence comprises 9-10, 9-11, or 10-11 nucleotides. In some embodiments, the hybridization sequence comprises 10 nucleotides.

[0051] In some embodiments, the hybridization sequence comprises the complete sequence of the nickase recognition sequence. In some embodiments, the primer binding sequence comprises the complete sequence of the nickase recognition sequence. In some embodiments, the primer hybridization sequence comprises a partial sequence of the nickase recognition sequence and the primer binding sequence comprises the complete sequence of the nickase recognition sequence. In some embodiments, the primer comprises a partial sequence of a first nickase recognition sequence and the primer binding sequence comprises a second partial recognition sequence, and the partial sequence of the first nickase recognition sequence and the partial sequence of the second nickase recognition sequence together form the complete sequence of the nickase recognition sequence formed during extension.

[0052] In some embodiments, the primer binding sequence and the additional sequence of the target polynucleotide are not reverse complementary to each other. In some embodiments, the primer binding sequence and the additional sequence of the target polynucleotide are orthogonal to each other. In some embodiments, the composition comprises a second primer having a hybridization sequence that is complementary to the reverse complementary sequence of the additional sequence of the target polynucleotide and is not complementary to the primer binding sequence of the target polynucleotide.

[0053] Stabilizing Sequence In some embodiments, the primer further comprises a stabilizing sequence extended from its 5' end. The stabilizing sequence provides a template for extension of the target polynucleotide (or its reverse complement) following primer binding (FIG. 1B). In addition, in some embodiments, the stabilizing sequence remains duplexed with the extended target polynucleotide after nickase cleavage so that the primer can be extended by DNA polymerase (DNAP) (see FIG. 1C and FIG. 1D). In some embodiments, the stabilizing sequence comprises 6-30 nucleotides. In some embodiments, the stabilizing sequence is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the stabilizing sequence is 16-22 nucleotides. In some embodiments, the stabilizing sequence is 18 nucleotides. In some embodiments, the stabilizing sequence further comprises an RNA polymerase binding sequence (e.g., a T7 polymerase binding sequence). In some embodiments, the stabilizing sequence comprises the sequence 5'-GAAGGTCGAAGATCGC-3' (SEQ ID NO: 3).

[0054] In some embodiments, the primer is [ka] (Bold indicates hybridization sequence) (SEQ ID NO:4).

[0055] Blocking Molecules In some embodiments, the primer, the first and / or the second primer, comprises a blocking molecule on the last nucleotide at the 3' end of the primer. In some embodiments, the blocking molecule blocks extension of the primer in the 3' direction (e.g., stops extension from proceeding) by chemically modifying the 3'OH group of the 3'-terminal nucleotide of the primer. In some embodiments, the 3'OH chemical modification blocks a strand-displacing polymerase from adding an additional nucleotide to the 3'-terminal nucleotide of the primer. In some embodiments, the 3' blocking molecule may also inhibit exponential amplification of primer dimers.

[0056] In some embodiments, the 3' blocking molecule, when attached to the 3' end of the primer, blocks extension of the primer in the 3' direction. In some embodiments, the blocking molecule is attached to the 3' OH group of the 3' terminal nucleotide of the primer. In some embodiments, the blocking molecule is selected from the group consisting of: (1) 3'ddNTP (a dideoxynucleotide triphosphate lacking a 3'OH group required for elongation (e.g., ddTTP, ddATP, ddGTP, or ddCTP)); (2) 3'Inverted dT (having a 3'-3' bond that inhibits elongation), (3) a 3' carbon chain spacer (a carbon chain attached to the 3' OH group required for elongation. The spacer can be 4C, 5C, 6C, 7C, 8C, 9C, 10C, 11C, or 12C or more); (4) 3'-hexanediol (a C6 glycol chain attached to the 3'-OH group required for elongation); (5) 3' amino (a 4C, 5C, 6C, 7C, 8C, 9C, 10C, 11C, or 12C or greater carbon chain spacer with a methoxy group on C1 and an NH2 group attached to the last carbon of the spacer (4C, 5C, 6C, 7C, 8C, 9C, 10C, 11C, or 12C or greater). The amino spacer bonds to the 3' OH group required for elongation), and (6) 3' phosphorylation (the phosphate group attached to the 3' OH required for extension, so that the 5' phosphate group of the preceding nucleotide cannot attach to the 3' OH of the 3' terminal nucleotide on the primer).

[0057] In some embodiments, the blocking molecule is 3' hexanediol.

[0058] Nickase The method provided herein uses a nickase to (1) nick double-stranded DNA containing a primer to allow removal of a 3' blocking group during primer extension, and (2) nick double-stranded polynucleotide to allow strand displacement during extension. Nick, nicking, and nicked all refer to the cleavage of a single strand of a double-stranded DNA molecule (e.g., a target polynucleotide) by a nickase. A nickase as used herein can nick a specific nickase recognition sequence. The term cognate nickase is used to describe a nickase that pairs with a corresponding nickase recognition sequence. For example, Nb.BbvCI is cognate to 5'-CCTCAGC-3'.

[0059] In some embodiments, the composition further comprises a nickase, which is an enzyme capable of binding to a double-stranded polynucleotide and nicking (i.e., cleaving) only one of the strands. Nickases are well known in the art and are described in Zhang et al. Protein expression and purification 69.2 (2010): 226-234; Higgins et al. Nucleic acids research 29.12 (2001): 2492-2501; Morgan et al. (2000): 1123-1125; Xu et al. Proceedings of the National Academy of Sciences 98.23 (2001): 12990-12995; Heiter et al. Journal of molecular biology 348.3 (2005): 631-640; Zhu et al. Journal of molecular biology 337.3 (2004): 573-583; and Samuelson et al. Nucleic acids research 32.12 (2004): 101-102, each of which is incorporated herein by reference in its entirety. 3661-3671. In some embodiments, the nickase is cognate to a nickase recognition sequence on the target polynucleotide and / or primer. In some embodiments, the nickase nicks the double-stranded target polynucleotide product, which contributes to low temperature (e.g., 4-30° C. or 12-30° C.) isothermal displacement of the strands by the polymerase. In some embodiments, the nickase is selected from the group consisting of Nt.BspQI, Nt.CviPII, Nt.BstNBI, Nb.BsrDI, Nb.BtsI, Nt.AlwI, Nb.BbvCI, Nt.BbvCI, Nb.BsmI, Nb.BssSI, and Nt.BsmAI. In some embodiments, the nickase is Nb.BbvCI.Nickases may be associated with the recognition sequences: 5'-CCTCAGC-3' (Nb.BbvCI), 5'-GCTCTTC-3' (Nt.BspQI), 5'-CCT-3', 5'-CCG-3', or 5'-CCA-3' (Nt.CviPII), 5'-GAGTCNNNNN-3' (Nt.BstNBI), 5'-GCAATGNN-3' (Nb.BsrDI), 5'-GCAGTGNN-3' (Nb.BtsI), 5'-GGATCNNNNN-3' (Nt.AlwI), 5'-GAATGCN-3' (Nb.BsmI), 5'-CACGAG-3' (Nb.BssSI), and 5'-GTCTCNN-3' (Nt.BsmAI).

[0060] In some embodiments, the nickase recognition sequence is the complete sequence of the nickase recognition sequence. The complete sequence of the nickase recognition sequence is the sequence that is recognized and nicked by the nickase. The complete sequence of the nickase recognition sequence depends on the cognate nickase. For example, when Nb.BbvCI is the nickase, 5'-CCTCAGC-3' is the complete sequence of the nickase recognition sequence. When Nt.CviPII is the nickase, 5'-CCT-3', 5'-CCG-3', or 5'-CCA-3' is the recognition sequence. In some embodiments, the nickase recognition sequence is a partial sequence of the nickase recognition sequence. The partial recognition sequence is a sequence that has a part of the complete recognition sequence. The partial sequence of the nickase recognition sequence depends on the nickase. For example, when Nb.BbvCI is the nickase, 5'-CCT-3' is the partial sequence of the nickase recognition sequence. However, when Nt.CviPII is a nickase, 5'-CCT-3' is not a partial recognition sequence. A nickase partial recognition sequence includes consecutive nucleotides from the complete sequence of a nickase recognition sequence, and the partial recognition sequence includes the first or last nucleotide in the complete recognition sequence. In some embodiments, a partial sequence of a nickase recognition sequence does not include 1, 2, 3, 4, 5, 6, 7, 8, or 9 consecutive nucleotides included in the complete sequence of a nickase recognition sequence. In some embodiments, a partial sequence of a nickase recognition sequence does not include at least one (e.g., at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9) nucleotide included in the complete recognition sequence. In some embodiments, the partial sequence of the nickase recognition sequence does not include 1 to 2, 1 to 3, 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 2 to 3, 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 3 to 4, 3 to 5, 3 to 6, 3 to 7, 3 to 8, 3 to 9, 4 to 5, 4 to 6, 4 to 7, 4 to 8, 4 to 9, 5 to 6, 5 to 7, 5 to 8, 5 to 9, 6 to 7, 6 to 8, 6 to 9, 7 to 8, 7 to 9, or 8 to 9 nucleotides included in the complete sequence of the nickase recognition sequence.

[0061] In some embodiments, the hybridization sequence comprises the complete sequence of the nickase recognition sequence. In some embodiments, the primer binding sequence comprises the complete sequence of the nickase recognition sequence. In some embodiments, the primer hybridization sequence comprises a partial sequence of the nickase recognition sequence, and the primer binding sequence comprises the complete sequence of the nickase recognition sequence. In some embodiments, the primer comprises a partial sequence of a first nickase recognition sequence, and the primer binding sequence comprises a second partial recognition sequence, and the partial sequence of the first nickase recognition sequence and the partial sequence of the second nickase recognition sequence together form the complete sequence of the nickase recognition sequence formed during extension. For example, in some embodiments, the primer binding sequence is [ka] (SEQ ID NO:1), which sequence includes a partial Nb.BbvCI nickase recognition sequence (bold), and in these embodiments, the primer comprises [ka] (SEQ ID NO: 1), and the primer may contain a hybridization region that is the reverse complement of the remainder of the nickase recognition sequence (bold) ( [ka] (SEQ ID NO:5). Thus, extension of the target polynucleotide, in some embodiments, results in the complete sequence of the nickase recognition sequence.

[0062] Strand-displacing polymerase The methods provided herein amplify a target polynucleotide using a strand-displacing polymerase. Thus, in some embodiments, the composition further comprises a strand-displacing polymerase. The strand-displacing polymerase can displace downstream DNA during extension. In some embodiments, the strand-displacing polymerase has extension activity at low temperatures (e.g., 4-25°C). In some embodiments, the strand-displacing polymerase has extension activity at 13-25°C, 13-24°C, 13-23°C, 13-22°C, 13-21°C, 13-20°C, 13-19°C, 13-18°C, 13-17°C, 13-16°C, or 13-15°C. In some embodiments, the strand displacing enzyme has extension activity at 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, or 30°C. In some embodiments, the strand displacing polymerase has extension activity at room temperature. In some embodiments, the strand displacing polymerase is selected from the group consisting of Bsu DNA polymerase I (Bsu), phi29, Bst DNA polymerase, Klenow Large Fragment, Klenow Exo-, Bsu Large Fragment, Isopol, and Isopol SD+, or variants thereof. In some embodiments, the strand displacing polymerase is Bsu or a variant thereof. In some embodiments, the strand displacing polymerase is Klenow or a variant thereof.

[0063] Single-stranded binding protein The methods provided herein use single-stranded binding proteins to stabilize the strand displaced during extension. Single-stranded binding proteins and their applications are further described in Kur et al. Acta Biochimica Polonica 52.3 (2005): 569-574, which are incorporated herein by reference in their entireties. In some embodiments, the composition further comprises a single-stranded binding protein (SSBP). In some embodiments, the SSBP binds to the DNA strand displaced by the strand-displacing polymerase. In some embodiments, the SSBP is selected from the group consisting of T4 gene 32 protein (T4gp32), EcoSSB, TaqSSB, and TthSSB, as described in Kur et al. Acta Biochimica Polonica 52.3 (2005): 569-574 and Alberts et al. Nature 227, 1313-1318 (1970), both of which are incorporated herein by reference in their entireties. In some embodiments, the SSBP is T4gp32.

[0064] buffer solution The methods and compositions provided herein include a buffer that provides suitable reaction conditions for amplification and / or detection of a target polynucleotide. In some embodiments, the buffer comprises components that one of skill in the art would understand to be present in a buffer for DNA amplification. In some embodiments, the composition further comprises a buffer in which isothermal low-temperature amplification of a target polynucleotide can occur. In some embodiments, the buffer comprises deoxynucleotides (dNTPs). In some embodiments, the buffer comprises Tris or acetate. In some embodiments, the buffer comprises potassium ions (K + In some embodiments, the buffer contains potassium acetate or potassium chloride. In some embodiments, the buffer contains magnesium ions (Mg 2+). In some embodiments, the buffer comprises magnesium chloride. In some embodiments, the buffer comprises a polymerase chain reaction enhancer (e.g., dimethylsulfoxide (DMSO), glycerol, formamide, bovine serum albumin, ammonium sulfate, polyethylene glycol, gelatin, Tween 20, Triton X-100, or N,N,N-trimethylglycine (betaine)). In some embodiments, T7 RNA polymerase is active in the buffer. In some embodiments, Cas13 polymerase is active in the buffer. In some embodiments, Cas12 is active in the buffer. In some embodiments, SHERLOCK is active in the buffer. In some embodiments, the buffer comprises CutSmart buffer.

[0065] Detection of amplified polynucleotides In some aspects, the disclosure provides methods for generating multiple copies of a target polynucleotide by amplifying the target polynucleotide and then detecting the multiple copies.

[0066] As described below, detection can be performed in a one-pot reaction or a two-pot reaction. In a one-pot reaction, in some embodiments, reagents for amplification and detection of the target polynucleotide are present throughout the incubation. In a one-pot reaction, in some embodiments, a copy of the target polynucleotide is transcribed into RNA and then detected by an RNA-binding protein (e.g., Cas13). Cas13 cleaves the RNA during detection, and the secondary activity of Cas13 also cleaves the detector polynucleotide. The secondary activity of the Cas protein is the non-specific cleavage of a nucleic acid (e.g., a detector polynucleotide) that occurs when the crRNA:Cas complex is cleaving the target (e.g., a target polynucleotide) specified by the crRNA. Secondary activities are discussed in detail in Varble et al. "Trends in Genetics 35.6 (2019): 446-456, which is incorporated herein by reference in its entirety. In a two-pot reaction, in some embodiments, reagents for target nucleotide amplification are added to the composition first, followed by incubation. After incubation (and possibly amplification of the target polynucleotide), reagents for detection are added to the composition. In some embodiments, the reagents for detection include a DNA binding protein (e.g., Cas12). Cas12 cleaves copies of the target polynucleotide during detection. Thus, Cas12 can be added after incubation and amplification so as not to interrupt the amplification process.

[0067] One-pot reaction In some embodiments, both the amplification of the target polynucleotide and the detection of the copy of the target polynucleotide are performed in the same reaction (e.g., a one-pot reaction). The copy of the target polynucleotide is, in some embodiments, transcribed into RNA and then detected by an RNA binding molecule (e.g., Cas13). In some embodiments, the RNA binding molecule specifically recognizes RNA transcribed from the copy of the target polynucleotide or RNA transcribed from the reverse complement of the target polynucleotide. In such embodiments, the composition further comprises an RNA polymerase (described above), and the target polynucleotide is modified to include an RNA polymerase binding sequence as described above. In some embodiments, the RNA binding molecule is a protein that specifically recognizes RNA transcribed from the copy of the target polynucleotide. In some embodiments, the RNA binding molecule is a nuclease. In some embodiments, the nuclease has a nuclease secondary activity that activates a detectable molecule (described below) when bound to RNA. In some embodiments, the nuclease is a CRISPR Cas nuclease that binds to RNA. In some embodiments, the nuclease is Cas13. In some embodiments, the Cas13 is selected from the group consisting of Cas13a, Cas13b, Cas13c, or Cas13d. In some embodiments, the Cas13 is LwaCas13a, LbaC13a, CcaCas13b, PsmCas13b, or AsCas12a, as described in Kellner et al. Nature protocols 14.10 (2019): 2986-3012, which is incorporated by reference in its entirety. In some embodiments, the Cas13 is LbuCas13a. In some embodiments, the composition further comprises a crRNA that is complementary to an RNA transcribed from multiple copies of the target polynucleotide. In some embodiments, the crRNA forms a complex with a CRISPR Cas (e.g., Cas13a) and guides the CRISPR Cas to the RNA for degradation.

[0068] In some embodiments, the composition comprises a detector polynucleotide. The detector polynucleotide is used to detect copies of the target polynucleotide and / or reverse complements of the target polynucleotide. In some embodiments, the detector molecule comprises a detector polynucleotide comprising a quencher molecule at one end (5' or 3') and a detectable molecule (e.g., Iowa Black-RQ, Black Hole Quencher-1, Black Hole Quencher-2, and Iowa Black-ZEN FQ), a fluorophore (e.g., FAM, 6-FAM, Tye563, Cy3, ATTO550, TAMRA583, ATTO565, ROX, ATTO Rho101, TEX615, Texas Red-X, TYE665, or Cy5) at the other end. In some embodiments, the detector polynucleotide detects the binding and cleavage of multiple copies of the target polynucleotide by Cas13. The detector polynucleotide is cleaved by a secondary activity of the CRISPR Cas guide RNA complex (i.e., crRNA:Cas12) when the complex binds to and cleaves a copy of the target polynucleotide, as described in Kellner et al. Nature protocols 14.10 (2019): 2986-3012. In some embodiments, the quencher molecule is selected from the group consisting of Iowa Black-RQ, Black Hole Quencher-1, Black Hole Quencher-2, and Iowa Black-ZEN FQ. In some embodiments, the fluorophore is selected from the group consisting of Tye563, Cy3, ATTO550, TAMRA583, ATTO565, ROX, ATTO Rho101, TEX615, Texas Red-X, TYE665, and Cy5, and the quencher molecule is selected from the group consisting of Iowa Black and Black Hole Quencher-2. In some embodiments, the fluorophore is selected from the group consisting of FAM.6-FAM, ATTO488, TETi539, JOE, HEX, and ATTO532, and the quencher molecule is selected from the group consisting of Black Hole Quencher-1 and Iowa Black-ZEN FQ.In some embodiments, the detector polynucleotide comprises a 6-FAM fluorophore and a black hole quencher-1. In some embodiments, the detector polynucleotide comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides. In some embodiments, the detector polynucleotide comprises 5-10, 5-15, 5-20, 10-15, 10-20, or 15-20 nucleotides. In some embodiments, the detector polynucleotide comprises a polyU (polyuracil) sequence (e.g., 5-20 consecutive uracil nucleotides). In some embodiments, the detector polynucleotide comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more consecutive uracil nucleotides. In some embodiments, the detector polynucleotide comprises 5-10, 5-15, 5-20, 10-15, 10-20, or 15-20 consecutive uracil nucleotides. In some embodiments, the detector polynucleotide can be cleaved by Cas13 secondary activity.

[0069] As described above, in one-pot detection embodiments, the target polynucleotide includes or can be modified to include an RNA polymerase binding sequence that is used to transcribe an amplified copy of the target polynucleotide into RNA for detection by an RNA binding protein (e.g., Cas13). To perform the transcription, in some embodiments, the one-pot reaction further includes an RNA polymerase. In some embodiments, the RNA polymerase is a homologous RNA polymerase. The homologous RNA polymerase binds to an RNA polymerase binding sequence on the target polynucleotide. In some embodiments, the RNA polymerase is a bacterial RNA polymerase. In some embodiments, the RNA polymerase is a eukaryotic RNA polymerase. In some embodiments, the RNA polymerase is a bacteriophage RNA polymerase. In some embodiments, the RNA polymerase is RNA polymerase I, RNA polymerase II, RNA polymerase III, RNA polymerase IV, RNA polymerase V, Nr virion RNA polymerase, or T7 RNA polymerase. In some embodiments, the RNA polymerase is T7 RNA polymerase.

[0070] Two-pot reaction In some embodiments, the amplification of the target polynucleotide and the detection of the copies of the target polynucleotide are performed in separate or sequential reactions. In such reactions, the copies of the target polynucleotide can be directly detected using a DNA binding molecule. In some embodiments, the composition comprises a DNA binding molecule that specifically recognizes the copies of the target polynucleotide or the reverse complement of the target polynucleotide. In some embodiments, the DNA binding molecule is a nuclease. In some embodiments, the nuclease has a nuclease secondary activity that cleaves the detector molecule when bound to DNA (see below). In some embodiments, the nuclease is a CRISPR Cas nuclease that binds to DNA. In some embodiments, the nuclease is Cas12. In some embodiments, the Cas12 is selected from the group consisting of Cas12a or Cas12b. In some embodiments, the Cas12 is LbaCas12a or AsCas12a. In some embodiments, the composition further comprises a guide RNA that is complementary to the target polynucleotide or its amplicon. The guide RNA forms a complex with CRISPR Cas (e.g., Cas12a) and guides the CRISPR Cas to the target polynucleotide or its amplicon for degradation. In some embodiments, detection in a two-pot reaction can be achieved using Cas13 as described above, except that a detection reagent is added to the composition after incubation.

[0071] In some embodiments, the composition comprises a detector polynucleotide comprising a quencher at the 5' or 3' end and a fluorophore at the other end. The detector polynucleotide is cleaved by the CRISPR Cas guide RNA complex upon binding and cleavage of the target polynucleotide or its amplicon. In some embodiments, the quencher of the detector polynucleotide is selected from the group consisting of Iowa Black-RQ, Black Hole Quencher-1, Black Hole Quencher-2, and Iowa Black-ZEN FQ. In some embodiments, the fluorophore is selected from the group consisting of Tye563, Cy3, ATTO550, TAMRA583, ATTO565, ROX, ATTO Rho101, TEX615, Texas Red-X, TYE665, and Cy5, and the quencher is selected from the group consisting of Iowa Black and Black Hole Quencher-2. In some embodiments, the fluorophore is selected from the group consisting of FAM, 6-FAM, ATTO488, TETi539, JOE, HEX, and ATTO532, and the quencher is selected from the group consisting of black hole quencher-1 and Iowa Black-ZEN FQ. In some embodiments, the detector polynucleotide comprises a 6-FAM fluorophore and a black hole quencher-1. In some embodiments, the detector polynucleotide is added to the composition at the same time that the CRISPR Cas nuclease is added to the composition. In some embodiments, the detector polynucleotide comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 or more nucleotides. In some embodiments, the detector polynucleotide comprises 5-10, 5-15, 5-20, 10-15, 10-20, or 15-20 nucleotides. In some embodiments, the detector polynucleotide can be cleaved by Cas12 secondary activity.

[0072] In some embodiments, detection is accomplished using SHERLOCK, as described below.

[0073] Sherlock Detection In some embodiments, the multiple copies of the target polynucleotide are detected using a specific high sensitivity enzyme reporter unlocking (SHERLOCK) system as described in Kellner et al. Nature protocols 14.10 (2019): 2986-3012, which is incorporated herein by reference in its entirety. The SHERLOCK system may include an RNA guide for a Cas12a or Cas12b enzyme that targets a sequence within the multiple copies of the target polynucleotide, such that the presence of amplified target polynucleotide DNA induces a nuclease secondary activity of the Cas12a or Cas12b enzyme. The SHERLOCK system may also include an RNA guide for a Cas13a or Cas13b enzyme that targets a sequence within the multiple copies of the target polynucleotide, such that the presence of RNA transcribed by an RNA polymerase using the amplified target polynucleotide as a template induces a nuclease secondary activity of the Cas13a or Cas13b enzyme. In either system, detection of Cas12a, Cas12b, Cas13a, or Cas13b nuclease activity can be achieved by cleavage of a target polynucleotide that includes a sequence flanked by a detectable molecule and a quencher molecule. In some embodiments, the Cas13-based SHERLOCK assay can be used in a one-pot reaction. In some embodiments, the Cas12 or Cas13-based SHERLOCK assay can be used in a two-pot reaction.

[0074] method In some aspects, the disclosure provides methods for generating multiple copies of a target polynucleotide using the compositions described herein. As used herein, multiple copies refers to at least one copy (e.g., at least 2, at least 10, at least 100, at least 10 copies) of a target polynucleotide. 3 , at least 10 4 , at least 10 5 , at least 10 6 , at least 10 7 , at least 10 8 , or at least 10 9In some embodiments, multiple copies of a target polynucleotide are sufficient to be detected using a DNA or RNA binding protein (e.g., SHERLOCK). In some embodiments, the method of making multiple copies of a target polynucleotide is exponential amplification.

[0075] In some embodiments, the method includes incubating a composition described herein in a buffer to generate multiple copies of the target polynucleotide. In some embodiments, the buffer is sufficient to support amplification of the target polynucleotide to generate multiple copies of the target polynucleotide. In some embodiments, amplification of the target polynucleotide can be initiated when at least the following components are mixed in the buffer: target polynucleotide, primer, SSBP, nickase, and strand-displacing polymerase.

[0076] In some embodiments, the incubation is at isothermal conditions (i.e., isothermal incubation). Isothermal conditions are performed at a temperature that does not change or hardly changes during the incubation. In some embodiments, room temperature incubation is an isothermal condition. In some embodiments, isothermal conditions may vary in temperature by about 2, 3, 4, 5, or 6 degrees Celsius. In some embodiments, temperature fluctuations during isothermal incubation are not necessary for amplification or detection of target polynucleotides. In some embodiments, the incubation is at about 1° C. to about 99° C. In some embodiments, the incubation is at 4° C. to 50° C. In some embodiments, the incubation is at 4° C. to 37° C. In some embodiments, the incubation is at 4° C. to 30° C. In some embodiments, the incubation is at 4° C. to 25° C. In some embodiments, the incubation is at 4° C. to 20° C. In some embodiments, the incubation is at 4° C. to 15° C. In some embodiments, the incubation is at 4° C. to 10° C. In some embodiments, the incubation is between 12°C and 30°C. In some embodiments, the incubation is between 16°C and 30°C. In some embodiments, the incubation is between 12°C and 25°C. In some embodiments, the incubation is between 13°C and 25°C. In some embodiments, the incubation is between 14°C and 25°C. In some embodiments, the incubation is between 15°C and 25°C. In some embodiments, the incubation is between 16°C and 25°C. In some embodiments, the incubation is between 16°C and 22°C. In some embodiments, the incubation is at about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30°C.

[0077] In some embodiments, the incubation is for at least 10 minutes (e.g., at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 45 minutes, at least 1 hour, at least 1.5 hours, at least 2 hours, at least 3 hours, at least 4 hours, at least 6 hours, or at least 12 hours). In some embodiments, the incubation is for 10-30 minutes, 10-50 minutes, 10-60 minutes, 30-60 minutes, 30-90 minutes, 30-120 minutes, 30-180 minutes, or 30-240 minutes. In some embodiments, the incubation is for 1-2 hours, 1-3 hours, 1-4 hours, 1-6 hours, 2-3 hours, 2-4 hours, 2-5 hours, 2-6 hours, 3-4 hours, 3-5 hours, 3-6 hours, 4-5 hours, or 4-6 hours. In some embodiments, the incubation is for about 2 hours.

[0078] In some embodiments, the method further comprises detecting multiple copies of the target polynucleotide. In some embodiments, the detection reagents are Cas12 or Cas13 protein, a crRNA that is complementary to the target polynucleotide, and a detector polynucleotide. In some embodiments, the detector polynucleotide is cleaved when the Cas12 or Cas13 protein cleaves the multiple copies of the target polynucleotide or the RNA encoding the multiple copies of the target polynucleotide. In some embodiments, the reagents for detecting multiple copies of the target polynucleotide are present in the composition when incubation is initiated (e.g., the one-pot reaction described above). In some embodiments, the reagents for detecting multiple copies of the target polynucleotide are present in the composition when the sample is added (e.g., the one-pot reaction described above).

[0079] In some embodiments, reagents for detecting multiple copies of target polynucleotides are added after a designated time of incubation (e.g., a two-pot reaction as described above). The designated time for adding detection agents can be any of the incubation times described above. In some embodiments, detection agents are added at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 60 minutes, at least 90 minutes, or at least 120 minutes after amplification. In some embodiments, detection agents are added after about 2 hours of incubation.

[0080] In some embodiments, the detection is performed using SHERLOCK.

[0081] In some embodiments, the detection of multiple copies of the target polynucleotide is determined visually by identifying a color change in the composition, hi some embodiments, the detection of multiple copies of the target polynucleotide is determined using a fluorometer. EXAMPLES

[0082] Example 1: The CRISDA platform is not robust at low temperature amplification Contrary to the claims of Zhou et al., the CRISDA platform does not robustly amplify or detect the 220 aM dsDNA target at 25 °C (Zhou et al. Nature Comm. vol. 9, no. 1, 2018, Supplementary Figure 4). In an attempt to replicate this single experiment, the effective detection limit for the ssDNA target was found to be approximately 3 orders of magnitude worse than claimed, despite optimization of both primer and single-stranded binding protein concentrations (Figure 2).

[0083] Example 2: Strand Displacement Amplification for Use at Low Temperatures Conventional strand displacement amplification (SDA) reactions rely on a three-step process that begins with a dsDNA product containing a reciprocal nickase recognition sequence. First, a nickase cleaves at the target sequence, making a free 3'OH terminus available. Second, a strand-displacing DNA polymerase extends from the free 3'OH, displacing the top strand of the dsDNA duplex beyond the nicked sequence. Third, a primer binds to the nickase recognition sequence in a reverse-complementary orientation, and a DNA polymerase extends the primer, generating a copy of the initial dsDNA. In this way, the dsDNA is exponentially amplified with nicking and extension events that generate ssDNA copies that can later form duplexes again. However, this SDA reaction is not robust at low temperatures (e.g., below about 25°C).

[0084] The failure mode of the SDA reaction at low temperatures was not immediately clear. Initially, it was suspected that the reaction rates of the two enzymes involved (nickase and strand-displacing polymerase, Nb.BbvCI and Klenow LF, respectively) were too slow to result in efficient amplification. However, when the rate of nicking and strand-displacement that took place at room temperature compared to high temperatures was evaluated, this alone could not explain the dramatic drop in sensitivity observed. Instead, some reduction in reaction rate was exacerbated to the extent that primer-dimer products formed before sufficient levels of copies of the target polynucleotide could be made (Figure 3). In theory, the single-stranded binding protein (SSB, T4gp32) in the reaction is intended to prevent this by artificially increasing the melting temperature of the nucleic acid, but the detection limit did not appear to be improved even at higher concentrations of SSB protein (Figure 3).

[0085] At higher temperatures (typically 37-55 °C, Zhou et al. Nature Comm. 2018 and Biolabs, New England. “Isothermal Amplification & Strand Displacement.”) primer dimer formation was less important and likely a key bottleneck for the low-temperature performance of the reaction. In initial design iterations, it was hypothesized that shortening the primer length would eliminate primer dimer pool species containing correctly paired nickase recognition sequences that could induce further exponential amplification of the dimers. Standard designs for forward and reverse SDA primer pairs require that they are greater than 14 nt in length, typically ranging from 20 to 40 nt (Figure 4) (Zhou et al. Nature Comm. 2018, Biolabs, New England. “Isothermal Amplification & Strand Displacement.” and Shi et al. Analytical Chemistry, vol. 86, no. 1, 2013, pp. 336-339). Using a novel short single primer design with a hybridization sequence of only 9 nt (both the forward and reverse binding sequences are identical), experiments showed linear, rather than exponential, primer-dimer formation (Figure 5).

[0086] With this optimized primer, up to one order of magnitude more copies of the ssDNA target could be detected within a 2-h reaction time using Cas12a as the amplicon detector (Figure 6A and Figure 6B). This low attomoral LOD (~20 aM) achieved at ambient temperature surpassed both the RISDA platform originally reported by the authors and the CRISDA platform specifically mentioned herein. Further improvements were made by replacing LbaCas12a with LwaCas13a as the amplicon detector. The inclusion of T7 RNAP and rNTPs in the reaction and the T7 promoter sequence at the 5' end of the amplification primers allowed the SDA amplification step and the Cas13 detection step to be combined in one pot for real-time detection of the ssDNA trigger (Figure 7A). The resulting assay was able to consistently detect concentrations of 1 cp / μL (~2 aM) (Figure 7B and Figure 7C).

[0087] Despite the dramatic increase in sensitivity due to the novel short primers, there was further opportunity to optimize the system. Importantly, primer dimers continued to form, albeit more slowly, in the form of inactive non-nicking species. This did not prevent detection of the ssDNA target, but reduced the robustness of the system, especially when other "background" ssDNA oligos were added (Figure 8). The cause of this inhibitory interaction was not fully understood, but it was generally hypothesized that the continued ability of short primers to extend nonspecifically, even if the primer dimers formed were not exponentially amplified, led to off-target processes exacerbated by the presence of "fouling / background" free 3' ends. Again, this highlights the difficulty of performing isothermal amplification at low temperatures.

[0088] To remove this obstacle, a further novel iteration of the short primer was designed. In this design, a 3' hexanediol blocking molecule was added to the short primer. This blocking group prevents the primer from being extended by the polymerase alone, so that no off-target products can be formed, either exponentially or non-exponentially. The 3' blocked end does not prevent nicking by a nickase. Once nicked, the 3' end is released internally within the primer which can be extended by DNA polymerase, effectively unblocking the primer. Thus, following the initial nicking, a normal double-stranded amplicon capable of subsequent nicking and strand displacement is generated, despite the primer being initially blocked. As shown in Figure 8, this results in a system that can amplify low copy number ssDNA targets even in the presence of "fouling / background" oligos, dramatically improving robustness.

[0089] The challenge of adapting isothermal amplification techniques for reduced ambient temperatures has been largely unaddressed since the first design iterations over 20 years ago. Although lower catalytic activity of enzymes at ambient temperatures compared to the 37-55 °C temperature range can adversely affect amplification, a larger bottleneck for sustaining amplification at such temperatures has been shown to be the generation of primer dimers. By improving this through novel primer designs, it has been shown that amplification can be sustained at lower temperatures where the limit of detection is close to single digit copy numbers.

[0090] Example 3: Amplification of target polynucleotides using various strand-displacing polymerases Various polymerases can be used to amplify femtomolar (fM) amounts of target polynucleotide to detectable levels. The DNA polymerases (DNAPs) tested were Klenow Exo-DNAP, Bsu DNAP, IsoPol DNAP, and IsoPol SD+ DNAP. The starting concentrations of target polynucleotide were 0 fM, 2 fM, 20 fM, and 200 fM. Detection was performed using the Cas13a fluorophore quencher (FQ) reporter. The results showed that each polymerase was capable of amplifying target polynucleotide at fM concentrations sufficient for detection. Amplification of Klenow Exo-DNAP, Bsu DNAP, and IsoPol DNAP was sufficient to detect 2 fM of starting target polynucleotide after approximately 90-120 minutes of incubation. See Figure 9.

[0091] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter each refers to, and in some cases may be incorporated in their entirety.

[0092] The indefinite articles "a" and "an," as used in the specification and claims, unless otherwise specified, should be understood to mean "at least one."

[0093] Also, unless specifically stated otherwise, in any method claimed herein that includes multiple steps or acts, it should be understood that the order of the method steps or acts is not necessarily limited to the order in which the method steps or acts are recited.

[0094] In the claims and in the above specification, the words "comprising," "including," "carrying," "having," "containing," "involving," "holding," and "composed of," etc., are understood to be open-ended, i.e., meaning including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" are closed or semi-closed transitional phrases, respectively, as defined in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

[0095] The terms "about" and "substantially" preceding a numerical value mean ±10% of the recited numerical value.

[0096] Where a range of values ​​is given, each value therebetween, including the upper and lower limits of the range, is specifically contemplated and described herein.

Claims

1. (a) a target polynucleotide comprising a primer binding sequence, the primer binding sequence comprising a nickase recognition sequence; and (b) a primer comprising a hybridization sequence complementary to said primer binding sequence, wherein (i) said primer further comprises a 3' blocking molecule, and / or (ii) said hybridization sequence consists of 8 to 12 contiguous nucleotides complementary to said primer binding sequence.

2. The composition of claim 1 , wherein the target polynucleotide is single-stranded.

3. The composition of claim 1 or 2, wherein the nickase recognition sequence is a partial or complete nickase recognition sequence.

4. The composition of any one of claims 1 to 3, wherein the primer binding sequence is in the 5' terminal region of the target polynucleotide.

5. The composition of any one of claims 1 to 4, wherein the target polynucleotide comprises an additional sequence which is the reverse complement of the primer binding sequence.

6. The composition of claim 5 , wherein the additional sequence is in the 3′ terminal region of the target polynucleotide.

7. The composition of any one of claims 1 to 6, wherein the 3' blocking molecule is selected from 3' hexanediol, 3' ddC, 3' inverted dT, 3' carbon chain spacer, 3' amino, and 3' phosphorylation.

8. The composition of any one of claims 1 to 7, wherein the primer further comprises a stabilizing sequence 5' to the nickase recognition sequence, and optionally the stabilizing sequence consists of 6 to 30 nucleotides or 18 nucleotides.

9. 9. The composition of any one of claims 1 to 8, wherein the target polynucleotide is present in the composition at a concentration of less than 100 attomoral.

10. 10. The composition of any one of claims 1 to 9, further comprising a cognate nickase, a single-stranded binding protein, a strand-displacing polymerase, or any combination thereof.

11. 11. The composition of claim 10, wherein the homologous nickase is selected from Nb.BbvCI, Nt.BspQI, Nt.CviPII, Nt.BstNBI, Nb.BsrDI, Nb.BtsI, Nt.AlwI, Nt.BbvCI, Nb.BsmI, Nb.BssSI, and Nt.BsmAI.

12. 12. The composition of claim 10 or 11, wherein the single-stranded binding protein is selected from T4 gene 32 protein (T4gp32), Tth RecA, and ET SSB.

13. 13. The composition of any one of claims 10 to 12, wherein the strand displacing polymerase is selected from Bsu DNA polymerase I (Bsu), phi29, Bst DNA polymerase, Klenow Large Fragment, Klenow Exo-, Bsu Large Fragment, Isopol, and Isopol SD+.

14. 14. The composition of any one of claims 1 to 13, further comprising: (i) a Cas13a or Cas13b protein; (ii) a detector polynucleotide comprising a sequence flanked by a detectable molecule and a quencher molecule; (iii) a crRNA; and (iv) an RNA polymerase, wherein the target polynucleotide further comprises a cognate RNA polymerase binding sequence, and optionally the crRNA comprises a sequence that binds to RNA transcribed from the target polynucleotide.

15. 15. A method comprising incubating the composition of claim 14 in a buffer to generate multiple copies of the target polynucleotide.

16. 16. The method of claim 15, wherein the incubating is at about 4 degrees Celsius to about 30 degrees Celsius or about 16 degrees Celsius to about 25 degrees Celsius.

17. 17. The method of claim 15 or 16, wherein the incubating is under isothermal conditions.

18. 18. The method of any one of claims 15 to 17, further comprising detecting the multiple copies of the target polynucleotide, optionally wherein said detecting uses Specific High Sensitivity Enzyme Reporter Lock Unlock (SHERLOCK).

19. 14. A method comprising incubating the composition of claim 13 in a buffer to generate multiple copies of the target polynucleotide.

20. 20. The method of claim 19, wherein the incubating is at about 4 degrees Celsius to about 30 degrees Celsius or about 16 degrees Celsius to about 25 degrees Celsius.

21. 21. The method of claim 19 or 20, wherein the incubating is under isothermal conditions.

22. 22. The method of any one of claims 19 to 21, further comprising incubating the multiple copies of the target polynucleotide with (i) Cas13a or Cas13b protein, (ii) a detector polynucleotide comprising a sequence flanked by a detectable molecule and a quencher molecule, (iii) crRNA, and (iv) an RNA polymerase, wherein the target polynucleotide further comprises a cognate RNA polymerase binding sequence, and the crRNA comprises a sequence that binds to RNA transcribed from the target polynucleotide.

23. 23. The method of claim 22, further comprising detecting the multiple copies of the target polynucleotide, optionally wherein said detecting uses a specific sensitive enzyme reporter unlock (SHERLOCK).

24. 14. A method comprising incubating the composition of claim 13 in a buffer to generate multiple copies of the target polynucleotide.

25. 25. The method of claim 24, wherein the incubating is at about 4 degrees Celsius to about 30 degrees Celsius or about 16 degrees Celsius to about 25 degrees Celsius.

26. 26. The method of claim 24 or 25, wherein the incubating is under isothermal conditions.

27. 27. The method of any one of claims 24-26, further comprising incubating the multiple copies of the target polynucleotide with a Cas12a protein, a crRNA, and a detector polynucleotide comprising a detector sequence flanked by a detectable molecule and a quencher molecule, wherein the crRNA comprises a sequence that binds to the target polynucleotide or a reverse complement of the target polynucleotide.

28. 28. The method of claim 27, further comprising detecting the multiple copies of the target polynucleotide, optionally wherein said detecting uses a specific sensitive enzyme reporter unlock (SHERLOCK).